31 results about "Lung tumours" patented technology

The invention concerns a radiofrequency (RF) ablation catheter (100) comprising: a flexible shaft (110) extending between a distal end and a proximal end: an inflatable balloon (120) mounted on the shaft (110); and an RF conductor element (115), wherein a portion of the flexible shaft (110) is distal to the inflatable balloon (120) and is defined as a distal segment (119) of the shaft (110), and wherein the RF conductor element (115) is located on the distal segment (119) and is adapted to electrically contact and to deliver RF energy to a liquid metal (150).

The present application provides a therapeutic combination of a quinoline derivative and an antibody, which comprises an immune checkpoint inhibitor and a tyrosine kinase inhibitor, wherein the tyrosine kinase inhibitor is a compound of formula I or a pharmaceutically acceptable salt thereof. The therapeutic combination in the present application shows good activity against lung tumor and liver tumor.

Two major treatment strategies employed in fighting non-small cell lung cancer (NSCLC) are tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs). The choice of strategy is based on heterogeneous biomarkers expressed by the lung tumor tissue. A major challenge for molecular testing of these biomarkers is the insufficiency of biopsy specimens from patients with advanced NSCLC. Disclosed herein is a method for predicting a response to immune-checkpoint blockade immunotherapy. The method generally involves imaging the subject with positron emission tomography with 2-deoxy-2-[fluorine-18] fluoro-D-glucose integrated with computed tomography to produce 18F-FDG PET / CT images of the tumor, analyzing the images using PET, CT, and Kulbek Leibler Divergence statistical (KLD) features or, alternatively using deep leaning such as Neural Networks; generating a radiomic signature from the identified features or Network characteristics; and computing a radiomic score based on the radiomic signature that is predictive of responsiveness to ICIs or TKIs.

The present invention relates to a treatment of cancer. Here, the inventors discovered that flavin-containing monooxygenase 4 (FM04) expression was increased in lung tumor samples compared with lung healthy tissue. They found that this phenotype was a common feature in lung adenocarcinoma promoted also by translocation of EML4 / ALK as well as by oncogenic KRAS or EGFR using dedicated mouse models. Moreover, FMO4 was strongly increased in human lung tumors compared with healthy lung tissue, and FMO4 expression was inversely correlated with overall survival in patients with lung adenocarcinoma. Importantly, FMO4 protected lung cancer cells against reactive oxidative species-induced apoptosis. Finally, FMO4 loss of function decreased oncogenic KRAS-induced human bronchoalveolar cells transformation in vitro and in vivo. Thus, the present invention relates to an FMO inhibitor for use in the treatment of cancer in a subject in need thereof.

The invention discloses an auxiliary lung cancer examination tool based on biological tissue fibrous structure morphological analysis, which is characterized in that the morphological condition of a biological tissue fibrous structure in an extracellular matrix is analyzed through multi-photon microscopic imaging, and an auxiliary lung cancer examination model is established; morphological multivariate parameter quantitative characterization is performed on an elastic fiber image and a collagenous fiber image, and then the similarity degree of the two fibers on multiple morphological characteristics is comprehensively characterized on the basis, so that a normalized similarity index map is generated. According to the method, the distribution information of the elastic fibers and the collagenous fibers in the lung tissue extracellular matrix can be rapidly extracted, the lung tumor evolution level is judged according to the difference of morphological distribution similarity conditions of the two fibrous structures of a normal person and a lung cancer patient, and the method serves as a novel examination method provided by the invention. The method has great clinical transformation potential, can more accurately analyze the morphological condition of the fibrous structure of the biological tissue, and has greater application potential compared with the traditional method.

The present disclosure relates to the determination of lung cancer using miRNA ratios. The present invention provides methods of determining the presence of a lung tumor in a subject. Also provided are methods of determining the presence of an invasive lung tumor in a subject. In addition, methods of determining the risk of developing a lung tumor in a subject are provided. Also provided are methods of determining the risk of developing an invasive lung tumor in a subject. Also provided are methods of predicting the risk of developing or having a lung tumor in a subject. Also provided are methods of establishing lung cancer treatment options.

The present invention discloses a dual-targeting molecule based on hyaluronic acid and glucose, a preparation method and application thereof, in particular, a dual-targeting fluorescent probe and anti-tumor drug based on hyaluronic acid and glucose. The dual-targeting fluorescent probe utilizes the interaction between HA-CD44 and Glc-GLUT1 to simultaneously target the CD44 and GLUT1 receptors of tumors (e.g., lung tumors), and can deliver fluorescent molecules into tumor cells in a targeted manner, reducing the aggregation of fluorescent molecules in normal cells; at the same time, the tumor cell endocytosis efficiency of fluorescent molecules can be improved. The chemical structures of the two targeting molecules HA and glucose in the dual-targeting fluorescent probe are clear, and the covalent bond connection sites and compositions are clear. This feature provides dual-targeting molecules with very good research and application value in drug delivery system applications and innovative drug development.

A tool to create virtual lesions inside a 3D lung tumor image. The image can be an MRI or CT image of a patient's lung to be treated. This virtual pre procedural ablation allows the operator to identify optimal ablation sites and select the optimal ablation parameters for the given anatomy. Also, the actual procedure will be performed with the lung parenchyma surrounding the tumor preventing ultrasound to penetrate beyond the tumor walls. A diagnostic mode will guide the operator to optimize ablation parameters. This virtual pre ablation, the parenchymal ultrasound barrier and the diagnostic catheter operation should enable the operator to conduct the therapeutic procedure safe, fast and effective.

The invention is a model of research and methodology to explore the treatment options for a particular case of lung cancer as an adjuvant therapy after surgical removal of a lung tumor. In practice, the excised / removed tumor is usually examined in the pathology laboratory for revision of the diagnosis, but no functional testing is performed for its sensitivity to subsequent adjuvant 5 therapy. In addition, the tumor is disposed of as unnecessary waste. Our proposal is that the tumor remains should be harvested for cellular studies and, using the model and methodology developed and described herein, preliminary answers can be obtained within 2-3 weeks, predicting which chemotherapeutic agents are likely to have a stronger effect and which therapy is likely to be ineffective for an individual lung cancer patient.

The present invention relates to the therapeutic combinations comprising (a) the PARP-1 selective non-trapper inhibitor Compound 1 and (b) an alkylating agent or (c) a topoisomerase inhibitor and the use of said combinations in the treatment of cancer, in particular lung tumors or ovarian and gastric tumors.

The invention relates to the technical field of cryoablation, in particular to a cryoablation device for lung tumors. The device comprises an air supply assembly and a tympanic membrane. Through the design mode of the combined type puncture needle, the cavity formed in the inner end of the outer ring body is used for treating the inner tube body after puncture work is completed, the needle head attached with focus tissue can be hidden to the inner end of the cavity, and therefore the possibility that the needle head makes contact with healthy tissue and organs in the follow-up extraction work is reduced, and the risk of secondary infection is reduced; meanwhile, the outer side of the needle head in the storage process is scraped through the arranged gas supply assembly and the drum membrane, thrust generated in the storage process of the inner tube body acts on the gas supply assembly, gas generated by the gas supply assembly changes the size of the drum membrane, the drum membrane expands to make contact with the outer side of the needle head being stored, and therefore the needle head can be conveniently stored. The adhered focus tissue is scraped by utilizing the contact position of the two, so that the risk that focus cells are in contact with healthy tissues and organs is further reduced.

The invention relates to the technical field of medical clinic, in particular to a deep learning-based lung tumor ablation intelligent evaluation regulation and control method and a deep learning-based lung tumor ablation intelligent evaluation regulation and control system. The method comprises the following steps that a tumor area in a preoperative CT image and an ablation area in an intraoperative CT image are obtained, and a tumor mask and an ablation mask are generated respectively after the preoperative CT image and the intraoperative CT image are subjected to spatial registration; the coverage ratio of the volume of the ablation mask to the volume of the tumor mask is calculated, and the mass center offset distance of the tumor mask and the ablation mask is calculated; dividing the centroid offset distance by the coverage ratio to obtain an offset index; and identifying each risk structure in the ablation mask boundary expansion region, and measuring the nearest distance from each risk structure to the ablation mask boundary. According to the method, a quantitative mechanism between dynamic geometric behaviors and anatomical risks in the ablation process is constructed, an intelligent model capable of predicting complication risks is formed based on the quantitative mechanism, and the accuracy of microwave ablation is improved.

The invention provides a lung tumor early warning protein chip and application thereof. The protein chip comprises an antigen group, the antigen group comprises an antigen; the antibody corresponding to the antigen is p53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD, MAGE A4, SARS, ZPR1, FAM131A, GGA3, PRKCZ, HDAC1, GOLPH3, NSG1, CD84, EEA1, CEA, CYFRA211 and the like; the protein chip is used for early warning and evaluation of lung tumors, and the early warning and evaluation comprises the following steps: collecting serum of a to-be-detected crowd, detecting the serum by using the protein chip to obtain detection data, and then judging whether the to-be-detected crowd belongs to a low-risk, medium-risk or high-risk crowd according to a risk early warning model; the protein chip systematically detects tumor-related autoantibody risk factor signals by a high-throughput technology, and is used for risk early warning detection of lung tumors.

This invention relates to an antitumor agent based on respiratory tract symbiotic bacteria, its preparation method, and its application. Addressing the current clinical issue of the unclear role of respiratory flora in lung cancer patients' progression, we provide the first evidence that the respiratory tract symbiotic *Streptococcus osticulata* possesses antitumor activity. When *Streptococcus osticulata* is delivered back into the respiratory tract, it can stimulate an antitumor immune response, and its efficacy can be further enhanced by adenosylcobalamin. Currently, there is a lack of non-invasive, non-invasive inhaled treatments for lung cancer. The antitumor agent of this invention can be combined with novel non-invasive inhaled bacterial-metabolite immunotherapy to achieve a long-term chronic disease management model, representing a safe and transferable treatment approach. In addition to achieving effective lung tumor control when used alone, this therapy can synergistically enhance the efficacy of immunotherapy, inducing complete tumor regression in 50% of tumor-bearing mice.

The invention belongs to the technical field of disease diagnosis and molecular biology, and particularly relates to a methylated biomarker for distinguishing benign and malignant pulmonary nodules and application of the methylated biomarker. According to the method, DNA differential methylation analysis is carried out on a pulmonary nodule tissue sample, and 20 optimal methylation biomarkers are selected according to sensitivity to construct a prediction model. The prediction model has high sensitivity and specificity, can distinguish lung malignant nodules (namely lung tumors) and lung benign nodules based on tissue samples and predict the lung cancer occurrence risk, is high in model accuracy and good in sensitivity, and has important value for early screening of lung cancer patients and the like.

This invention discloses an auxiliary examination tool for lung cancer based on the morphological analysis of fibrous structures in biological tissues. It utilizes multiphoton microscopy to analyze the morphological characteristics of fibrous structures in the extracellular matrix, establishing an auxiliary examination model for lung cancer. The model performs multivariate parameter quantitative characterization of elastic and collagen fiber images, and then comprehensively characterizes the similarity of the two types of fibers across multiple morphological features, generating a normalized similarity index atlas. This invention can rapidly extract the distribution information of elastic and collagen fibers in the extracellular matrix of lung tissue. By assessing the difference in the morphological similarity of these two fibrous structures between normal individuals and lung cancer patients, it determines the level of lung tumor evolution, presenting a novel examination method. This method has significant clinical translational potential, enabling more accurate analysis of the morphological characteristics of fibrous structures in biological tissues, and has greater application potential compared to traditional methods.

The invention relates to an anti-tumor preparation based on respiratory tract symbiotic bacteria as well as a preparation method and application thereof, and provides evidence for the first time aiming at the problem that the respiratory tract flora of a lung cancer patient is not exact in lung cancer progression clinically at present, and the evidence shows that the respiratory tract symbiotic bacteria oral streptococcus has an anti-tumor effect; when the oral streptococcus is delivered back to the respiratory tract, the anti-tumor immune response can be stimulated, and the curative effect of the oral streptococcus can be further enhanced through cobamamide. At present, a non-invasive and non-invasive inhalation type treatment mode for treating lung cancer is lacked clinically, and the anti-tumor preparation can be combined with a novel non-invasive inhalation type bacterium-metabolite immunotherapy to realize a long-term chronic disease management mode, and is a safe and convertible treatment means. On the basis that effective lung tumor control can be realized through independent use, the therapy can synergistically enhance the curative effect of immunotherapy, and tumors are induced to completely subside on 50% of tumor-bearing mice.

The invention relates to pharmaceutical compositions comprising a zinc2+ salt and a γ-polyglutamic acid carrier, and, optionally, an NF-κB inhibitor as a tumor-sensitizing agent, and methods for using such compositions to treat tumors in patients. Methods include administering a liquid dosage form or a solid dosage form of a therapeutically effective amount of a Zn(II) salt and a γ-polyglutamic acid carrier to a patient in need thereof. Methods of treating a broad spectrum of human tumors, including tumors with a drug-resistant phenotype, using the disclosed compositions are provided. Tumors that respond to the pharmaceutical compositions disclosed herein include neuroendocrine (neuroblastoma), gastric, uterine, and lung tumors.

The invention relates to a lung tumor image segmentation method and device based on an improved U-Net model, and a medium, and the method comprises the following steps: obtaining a to-be-segmented lung tumor image, inputting a trained lung tumor image segmentation model based on the improved U-Net model, and obtaining a lung tumor image segmentation result; wherein the lung tumor image segmentation model based on the improved U-Net model comprises an encoder and a decoder, and the encoder performs down-sampling on an input image step by step through partial convolution and performs feature extraction; the encoder and the decoder are connected through jump connection, and a coordinate attention module is introduced into the jump connection and comprises a coordinate attention generation unit and a coordinate information embedding unit. And the coordinate information embedding unit corrects the features extracted by partial convolution based on the attention weights in the horizontal direction and the vertical direction generated by the coordinate attention generation unit. Compared with the prior art, the tumor target area can be efficiently and accurately delineated.

The invention discloses puerarin hydrogel for enhancing solid tumor removal capacity of CAR-NK (Chimeric Antigen Receptor-Natural Killer) therapy and application of the puerarin hydrogel. The injectable puerarin hydrogel is based on hydrogen peroxide reaction hydrogel formed by mixing (polyethylene glycol dimethyl) acrylate, ferrous chloride and puerarin. After the injectable puerarin hydrogel is fixed in a tumor, endothelial cells can be activated to generate nitric oxide, so that tumor blood vessels are expanded, tumor hypoxia is relieved, tumor immunosuppression is reversed, intratumor infiltration, survival and targeted killing functions of CAR-NK cells are promoted, growth of breast tumors and lung tumors is finally inhibited, and obvious toxic and side effects are not generated. The invention provides an effective strategy for reprogramming tumor immunosuppression to activate CAR-NK cells through injectable puerarin hydrogel so as to enhance solid tumor treatment, and application of the puerarin hydrogel or combined CAR-NK cells in preparation of a medicine for removing solid tumors through an effective CAR-NK therapy.

Cholesterol efflux pathways have anti-inflammatory and anti-proliferative properties that could be exploited in tumor biology to unravel cancer vulnerabilities. Using a mouse model of lungtumor bearing KRASG12D mutation, the inventors identified that disruption of cholesterol efflux pathways by specific inactivation of Abca1 and Abcg1 in epithelial cancer progenitor cells and to some extent in macrophages promoted a pro-tolerogenic tumor microenvironment (TME). In particular, the inventors show that cholesterol removal therapy with cyclodextrin inhalation also reduced tumor burden in progressing tumor by suppressing the proliferation and expansion of epithelial progenitor cells of tumor-origin. The inventors' results position cholesterol removal therapy as a putative metabolic target in lung cancer progenitor cells. The present invention relates to a method for the treatment of a lung cancer in a patient in need thereof comprising administering to the patient a therapeutically effective amount of cyclodextrin.

The invention relates to the technical field of medical images, in particular to an intelligent visual navigation method for a lung tumor ablation surgical robot based on image fusion. The method comprises the following steps: collecting a multi-source medical image, executing spatial alignment, and outputting a to-be-processed multi-source medical image; identifying a key anatomical structure of the to-be-processed multi-source medical image; generating a segmentation mask according to the key anatomical structure, and determining a target region by using the segmentation mask; obtaining a body surface area and an operable angle of the lung tumor ablation surgical robot; dividing safety candidate points in the body surface area according to the key anatomical structure; taking the tumor center of the target area as a target spot, and searching an obstacle avoidance path from the target spot to the safety candidate point; and planning a puncture path in the obstacle avoidance path by using the operable angle, and outputting puncture path data. Based on the medical image technology, the robot is assisted to complete accurate positioning and navigation control, so that the puncture precision and the operation safety are improved, and the risk in an operation is reduced.

The present invention relates anti-microbial antibody signatures related to lung tumors, including benign tumors and adenocarcinomas. Disclosed herein are antibody panels comprising antigens from bacteria and / or viruses for use in early and accurate diagnosis of lung cancer and for reducing false positive lung carcinoma diagnoses from CT screening.

The present invention belongs to the technical fields of disease diagnosis and molecular biology, and particularly relates to methylation biomarkers for differentiating benign and malignant pulmonary nodules and their applications. The present invention performs DNA differential methylation analysis on tissue samples of pulmonary nodules, and constructs a prediction model by selecting the optimal 20 methylation biomarkers according to sensitivity. This prediction model has high sensitivity and specificity, can distinguish pulmonary malignant nodules (i.e., lung tumors) from pulmonary benign nodules based on tissue samples, predict the risk of lung cancer occurrence, has high model accuracy and good sensitivity, and is of great value for early screening of lung cancer patients, etc.

The invention discloses a traditional Chinese medicine preparation for treating pulmonary nodules and resisting lung tumors and a preparation method, and belongs to the technical field of medicines for treating respiratory system diseases. Epimedium, rheum officinale, burdock, cimicifugae foetidae, folium isatidis, paris polyphylla, radix angelicae, asarum, almonds, asparagus cochinchinensis and dandelion are selected and cleaned, honey and sesame-flavor liquor are added for compatibility and decoction, and the traditional Chinese medicine preparation is prepared. The traditional Chinese medicine composition has an obvious treatment effect on reducing the number of pulmonary nodules and reducing the diameter of the pulmonary nodules, and can obviously relieve the inflammatory response of the pulmonary nodules, so that the aim of delaying or treating the pulmonary nodules and lung tumors is fulfilled.

The invention relates to a CT (Computed Tomography)-guided percutaneous puncture pulmonary nodule targeted tissue positioning method which comprises the following steps: acquiring perfusion images of pulmonary artery and bronchial artery, processing perfusion volume data of the perfusion images, acquiring pulmonary artery blood flow, bronchial artery blood flow and pulmonary artery perfusion indexes, and generating corresponding perfusion pseudo-color images; taking the blood supply area of the bronchial arterial blood flow as lung tumor tissues, and performing lung tumor area targeted localization according to color features in the perfusion pseudo-color graph of the bronchial arterial blood flow to obtain a target spot; the guide sheath needle based on magnetic navigation is used as a puncture positioning needle, and is positioned and punctured to lung tumor tissues according to a target spot for sampling. The accuracy and safety of pulmonary nodule pathological diagnosis are improved, complications are reduced, and a more reliable basis is provided for treatment of patients.

The present invention provides a method for recognizing, analyzing, constructing and processing special pathological images of the lungs, which is characterized in that it includes developing an identification model STASNet for the spread of cancer cells in air spaces in lung cancer based on digitized scanned lung tumor section images. Based on this model, the following objectives can be achieved: assisting pathologists to identify STAS lesions around lung pathological sections in real time during the diagnosis and treatment process, improving the efficiency of clinical diagnosis of STAS, and reducing misdiagnosis and missed diagnosis; on the basis of classifying the presence or absence of STAS, further assisting clinicians to complete semi-quantitative analysis of STAS, indicating the prognosis of patients, and helping doctors formulate personalized diagnosis and treatment plans; as an organic part of the microscope computer imaging system, embedding a microscope image acquisition module to identify STAS lesions in lung cancer images in real time.

The utility model relates to the technical field of thoracic surgery endoscope, and discloses a magnesium alloy cutting stitching instrument nail cabin, which comprises a nail cabin, and is characterized in that degradable magnesium-zinc alloy is used for preparing stitching nails, and the stitching nails are combined with titanium alloy nails for combined application, firstly, the titanium alloy nails are combined for combined application; the degradability of the suturing nail is considered, and meanwhile, a small number of titanium alloy nails are reserved to ensure the lasting physical strength of the wound suturing part; secondly, magnesium and zinc ions released when the magnesium-zinc alloy suturing nail is slowly degraded can continuously play an anti-tumor role at the cutting edge, the cutting edge distance can be properly shortened in a lung tumor operation, namely, the distance between a cutting line and the tumor edge when lung tissue is cut, the cutting edge distance which is currently recognized in the world is 2 cm, and then the purpose of retaining healthy lung tissue as much as possible is achieved; finally, the heights of the metal nails are gradually reduced from the outer side to the inner side, after the tissue is cut, the height of the metal nail closest to the cutting edge is the lowest, the provided suturing force is the largest, and the suturing effect can be fully guaranteed.

The invention discloses a medicine prepared from rare ginsenoside Rg5 and used for treating lung malignant tumors and a preparation method of the medicine, and relates to the technical field of medical drugs, and the medicine is prepared from the following components in parts by weight: 10-20 parts of rare ginsenoside Rg5, 10-15 parts of pH-liposome, 8-12 parts of curcumin-polyethylene glycol, 5-8 parts of ganoderan and 5-10 parts of beta-cyclodextrin. The pH-lipidosome is used as a carrier, and the carrier of the pH-lipidosome can adapt to the characteristics of a lung tumor microenvironment, so that rare ginsenoside Rg5, curcumin-polyethylene glycol and ganoderma lucidum polysaccharide can be guided to accurately tend to lung tumor tissues, non-specific distribution of drugs in normal lung tissues and other organs is reduced, and the curative effect is improved. The active ingredients are prevented from being wasted or degraded at non-target parts, so that the effect of efficiently enriching the medicine in lung tumor tissues is achieved, the targeting effect of the medicine on lung malignant tumors is enhanced, the targeting property of the medicine is improved, and the targeting inhibition effect of the medicine on lung cancer is improved.

Provided herein is technology for lung neoplasia screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of lung cancer.